# Stefano Gulla

> Stefano Gulla is the Amsterdam-based Chief Scientific Officer of Kling Biotherapeutics and a co-founder and former CEO and CSO of Abcuro. He earned a BSc in Biochemistry and a doctorate at Northeastern University, completed postdoctoral research at MIT, and held industry roles at Pfizer, Agenus, Repertoire Immune Medicines and RVAC Medicines.

- **Role:** Chief Scientific Officer at Kling Biotherapeutics
- **Organizations:** Kling Biotherapeutics, Abcuro, Inc., RVAC Medicines, Repertoire Immune Medicines, Agenus, Pfizer, Massachusetts Institute of Technology, Northeastern University
- **Education:** Bachelor of Science in Biochemistry, Northeastern University, PhD; subject not specified in appointment biography, Northeastern University, Postdoctoral training, Keating laboratory (not a degree), Massachusetts Institute of Technology
- **Known for:** Co-founded Abcuro and served as CEO and CSO., Kling’s appointment biography credits him with raising more than $60 million in venture funding at Abcuro., Co-author on research publications listed by the MIT Keating laboratory.

## Career timeline

- **2008-2010** — MIT postdoctoral period listed on LinkedIn; Keating lab confirms former postdoc status.
- **2010-2015** — Pfizer project leadership, per Dealroom work history.
- **2015-2016** — Agenus program and portfolio management, per Dealroom.
- **2015-2016** — Abcuro founding period: SEC gives incorporation in 2015; Kling appointment biography describes founding in 2016. Served as CEO and CSO.
- **2020** — Signed Abcuro Form D as President on July 6.
- **2021-2022** — Director role at Repertoire Immune Medicines, per Dealroom.
- **2022-2023** — Vice President at RVAC Medicines, per Dealroom.
- **2023** — Appointed Chief Scientific Officer of Kling on December 5.

## Achievements

- Co-founded Abcuro and served as CEO and CSO.
- Kling’s appointment biography credits him with raising more than $60 million in venture funding at Abcuro.
- Co-author on research publications listed by the MIT Keating laboratory.
- Led Kling’s platform team and scientific platform development, as described in his July 2025 public post.

## Latest updates

- **2025-07** — Kling announced a collaboration and license option agreement with Sanofi; Gulla publicly credited the platform team.
- **2025-09** — Appeared in episode 26 of the Base to Base Biotech podcast.
- **2026-10** — Kling’s current leadership page lists Stefano Gulla as CSO; verified October 14, 2026.

## Links

- Website: https://www.klingbio.com/stefano-gulla
- LinkedIn: https://www.linkedin.com/in/stefano-gull%C3%A0-2bb65a4/
- Twitter/X: https://x.com/StefanoGulla

---

Profile page: https://yespress.io/stefano-gulla
Published by YesPress — https://yespress.io
Last updated: 2026-10-14